» Articles » PMID: 36269700

Ocular Findings, Surgery Details and Outcomes in Proliferative Diabetic Retinopathy Patients with Chronic Kidney Disease

Overview
Journal PLoS One
Date 2022 Oct 21
PMID 36269700
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: We investigated the influence of impaired renal function on fundus characteristics, pars-plana vitrectomy (PPV) details, and outcomes in patients with proliferative diabetic retinopathy (PDR).

Design: A retrospective cohort study.

Methods: We investigated a consecutive series of PDR patients who underwent PPV. The diabetic complications, previous photocoagulation, intravitreal injections before PPV, ocular findings during PPV, surgical details, short-term visual outcome and post-PPV complications were recorded and compared between patients with and without impaired renal function.

Results: 149 patients had normal renal function (67.7%), and 71 (32.3%) patients had impaired renal function; 85.4% of patients were identified with chronic kidney disease (CKD) during the preoperative assessment. Impaired renal function was related to hypertension (3.40[1.58-7.29], p = 0.002), incomplete pan-retinal photocoagulation (PRP) (3.18[1.50-6.72], p = 0.002), severe fibrovascular membrane (8.19[3.43-19.54], p<0.001), and extensive retinal vascular closure (3.40[1.54-7.52], p = 0.002). There was a more frequent occurrence of severe intraoperative bleeding (56.3%, 32.2%, p = 0.001) and a higher percentage of intraocular subretinal fluid drainage (45.1%, 22.1%, p = 0.008) in patients with impaired renal function. The percentage of patients whose visual acuity (VA) increased was similar between the two groups (42.3%, 54.4%, p = 0.34).

Conclusions: In PDR patients, screening for CKD was required before PPV. PDR patients with impaired renal function tended to have more severe ischemic retinal conditions. Comparable PPV outcomes could be obtained in patients with and without impaired renal damage.

Citing Articles

Impact of gut microbiota and associated mechanisms on postprandial glucose levels in patients with diabetes.

Feng X, Deng M, Zhang L, Pan Q J Transl Int Med. 2023; 11(4):363-371.

PMID: 38130636 PMC: 10732577. DOI: 10.2478/jtim-2023-0116.

References
1.
Parikh R, Traband A, Kolomeyer A, VanderBeek B, Kim B, Maguire A . Intravitreal Bevacizumab for the Treatment of Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy. Am J Ophthalmol. 2017; 176:194-202. PMC: 5376507. DOI: 10.1016/j.ajo.2017.01.010. View

2.
Wang S, Chen R, Liu Q, Shu Z, Zhan S, Li L . Prevalence, awareness and treatment of chronic kidney disease among middle-aged and elderly: The China Health and Retirement Longitudinal Study. Nephrology (Carlton). 2015; 20(7):474-84. DOI: 10.1111/nep.12449. View

3.
Song P, Yu J, Chan K, Theodoratou E, Rudan I . Prevalence, risk factors and burden of diabetic retinopathy in China: a systematic review and meta-analysis. J Glob Health. 2018; 8(1):010803. PMC: 5997368. DOI: 10.7189/jogh.08.010803. View

4.
Takayama K, Someya H, Yokoyama H, Takamura Y, Morioka M, Sameshima S . Risk Factors of Neovascular Glaucoma After 25-gauge Vitrectomy for Proliferative Diabetic Retinopathy with Vitreous Hemorrhage: A Retrospective Multicenter Study. Sci Rep. 2019; 9(1):14858. PMC: 6795876. DOI: 10.1038/s41598-019-51411-6. View

5.
Rodriguez-Poncelas A, Mundet-Tuduri X, Miravet-Jimenez S, Casellas A, Barrot-De La Puente J, Franch-Nadal J . Chronic Kidney Disease and Diabetic Retinopathy in Patients with Type 2 Diabetes. PLoS One. 2016; 11(2):e0149448. PMC: 4757564. DOI: 10.1371/journal.pone.0149448. View